Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / July / Who Gets Access to Diagnostics
Infectious Disease Point of care testing Screening and monitoring Technology and innovation Research and Innovations

Who Gets Access to Diagnostics?

Designing low-cost pathogen detection tools for healthcare systems with limited resources

By Jessica Allerton 07/09/2026 Discussion 3 min read
  • Full Article
  • Summary
  • Listen
  • Report
  • Poll
  • Top Institutions

Share

Who Gets Access to Diagnostics?

Overview

Access to diagnostics for antimicrobial resistance (AMR) is uneven globally, particularly in low-resource settings. David Roach and his team are developing a low-cost, portable diagnostic platform aimed at improving access in these environments.

Background

Antimicrobial resistance (AMR) poses a significant global health challenge, yet the diagnostics necessary for detecting resistant infections are often inaccessible in low-resource settings. Limited infrastructure and high costs hinder the adoption of advanced diagnostic technologies.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • The BADLOCK platform is designed for rapid, portable detection of pathogens and resistance.
  • It aims to operate with minimal laboratory infrastructure and at a lower cost than existing diagnostic systems.
  • Key considerations for diagnostics in low-resource settings include low per-test costs and minimal infrastructure requirements.
  • Successful diagnostics must align with local healthcare needs and available resources.
  • Collaborations with local and international partners can help bridge diagnostic gaps in underserved regions.
  • Funding efforts should prioritize accessibility and scalability of AMR diagnostics.

Clinical Implications

The development of low-cost diagnostics specifically for AMR in low- and middle-income countries is critical. Ensuring these technologies are accessible and scalable can significantly impact patient care in regions most affected by AMR.

Conclusion

Addressing the diagnostic needs for AMR in low-resource settings is a global health priority that requires innovative, affordable solutions tailored to local contexts.

Related Resources & Content

  1. World Health Assembly, WHO, 2026 -- The World Health Assembly adopts updated Global Action Plan on Antimicrobial Resistance (2026–2036)
  2. Optometric Management — BUSINESS: CODING STRATEGY
  3. Optometric Management — DIAGNOSTIC DEVICES
  4. inside dentistry — Shop and Compare: Diagnostics
  5. retinal physician — Coding Q&A: Proper Documentation for Diagnostic Tests
  6. The World Health Assembly adopts updated Global Action Plan on Antimicrobial Resistance (2026–2036)
  7. Recommendations - WHO consolidated guidelines on tuberculosis - NCBI Bookshelf
  8. Impact of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a meta-analysis | BMC Infectious Diseases | Springer Nature Link

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

The Viral Frontier
Infectious Disease
The Viral Frontier

January 23, 2024

1 min read

The latest on the UK COVID-19 inquiry

What’s New in Infectious Disease? (December 2021)
Infectious Disease
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Infectious Disease
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

Pneumocystis Mysteries
Infectious Disease
Pneumocystis Mysteries

January 21, 2022

1 min read

What is the correct name for this pneumonia-causing pathogen?

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.